Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

At-Risk Launches: Three Cases May Determine How Damages Are Calculated

Executive Summary

How risky are at-risk launches of generic products?
Advertisement

Related Content

Introducing Hospira's New CEO And An Ambitious Five-Year Growth Plan
Pfizer Blocks Teva's Generic Lipitor In The U.K.
At-Risk Launches: Neurontin Settlement Leaves Question Of Jury Damage Calculations Unresolved
At-Risk Abundance: Generic Launch Gambles Usually Pay Off
Apotex To Retain About $300 Million From Its At-Risk Launch of Generic Plavix
Teva Could Face Damages Of $1.2 Billion For At-Risk Launch Of Generic Protonix
Teva Could Face Damages Of $1.2 Billion For At-Risk Launch Of Generic Protonix
Famvir Patent Settlement: 17 Months After At-Risk Launch, Teva Must Pay Novartis
Patent Fights In Brief: AstraZeneca And Wyeth Face Challenges
Anatomy Of A Patent Dispute: Purdue Pharma’s OxyContin Battle

Topics

Advertisement
UsernamePublicRestriction

Register

PS053414

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel